Acute Hypoxemic Respiratory Failure Following Mitral Transcatheter Edge‐to‐Edge Repair: The Role of Aortic Stenosis
- 23 April 2026
- journal article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 108 (1) , 189-196
Abstract
Background: The coexistence of severe mitral regurgitation (MR) and mild‐to‐moderate aortic stenosis (AS) presents diagnostic and therapeutic challenges. Limited data exists on outcomes following mitral transcatheter edge‐to‐edge repair (M‐TEER) therapy in this patient population. Aims: This study is aimed to evaluate clinical outcomes following M‐TEER in patients with mild‐to‐modearte AS compared with those without aortic stenosis. Methods: A single‐center retrospective study was conducted on 238 patients who underwent M‐TEER therapy between January 2014 and December 2024. Patients with severe AS, cardiogenic shock, and failed or aborted cases were excluded. We compared patients with mild‐to‐moderate AS ( n = 30) to those without AS ( n = 208). Primary outcome: Acute hypoxemic respiratory failure (AHRF) within 24 h (SpO 2 ≤ 90% ≥ 30 min or need for O 2 /NIV/IMV, adjudicated as cardiogenic). Secondary outcomes: Post‐procedural in‐hospital mortality, acute kidney injury, hospital length of stay (LOS), 30‐day rate of heart failure hospitalization (HFH), and 30‐day rate of all‐cause readmission. Multivariable logistic regression was used to identify independent predictors of AHRF, hospital LOS, and 30‐day HFH. Results: Following M‐TEER, the mild‐to‐moderate AS group experienced significantly higher rates of AHRF (16.7% vs. 3.8%, p = 0.0142; adjusted OR 4.38, 95% CI 1.36–14.61, p = 0.014). Within the parsimonious adjusted model, AS remained independently associated with AHRF, whereas the other included covariates were not. There was no significant difference in the 30‐day rate of all‐cause readmission, 30‐day rate of HFH, AKI, LOS, or in‐hospital mortality between groups. Conclusion: In patients undergoing M‐TEER, the presence of mild‐to‐moderate AS is independently associated with an increased risk of early post‐procedural AHRF, without differences in other short‐term clinical outcomes. Given the single‐center retrospective design and the limited number of clinical events, these findings should be considered hypothesis‐generating and warrant validation in larger, prospective, multicenter studies.Keywords
This publication has 26 references indexed in Scilit:
- Transcatheter Treatment of Residual Significant Mitral Regurgitation Following TAVRJACC: Cardiovascular Interventions, 2020
- Mitral Regurgitation in Low-Flow, Low-Gradient Aortic Stenosis Patients Undergoing TAVRJACC: Cardiovascular Interventions, 2020
- Why and How to Measure Aortic Valve Calcification in Patients With Aortic StenosisJACC: Cardiovascular Imaging, 2019
- Recommendations for Noninvasive Evaluation of Native Valvular RegurgitationJournal of the American Society of Echocardiography, 2017
- Pathophysiology and management of multivalvular diseaseNature Reviews Cardiology, 2016
- The Appropriate Use of Risk Scores⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.JACC: Cardiovascular Interventions, 2012
- Low-Flow, Low-Gradient Aortic Stenosis With Normal and Depressed Left Ventricular Ejection FractionJACC, 2012
- The Acute Hemodynamic Effects of MitraClip TherapyJACC, 2011
- Mitral regurgitationThe Lancet, 2009
- Burden of valvular heart diseases: a population-based studyThe Lancet, 2006